Controlled Non-Blinded Trial

Title Average Ratingsort descending
Clinical aspects of cancer treatment and new biochemical mechanisms of the drug Ukrain. 20.00%
Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolera 50.00%
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung 50.00%
Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit 50.00%
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe 50.00%
Ukrain therapy of stage T1N0M0 bladder cancer patients 60.00%
The association between degenerative hip joint pathology and size of the gluteus medius, gluteus minimus and piriformis muscles. 60.00%
Comparative evaluation of the efficiency of various Ukrain doses in the combined treatment of breast cancer. 65.00%
Efficacy of ukrain in the treatment of pancreatic cancer. 70.00%
Preliminary results of individual therapy of chronic hepatitis C by Ukrain and interferon-alpha. 70.00%
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and re 70.00%
Comparative evaluation of the complex treatment of rectal cancer patients (chemotherapy and X-ray therapy, Ukrain monotherapy) 80.00%
Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer 80.00%
NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial 85.00%
Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). 90.00%